Presentation is loading. Please wait.

Presentation is loading. Please wait.

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

Published byAshley Shaw Modified over 5 years ago

Similar presentations

Presentation on theme: "Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric."— Presentation transcript:

1 Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study. by Huining Kang, Edward J. Bedrick, I-Ming Chen, Carla S. Wilson, Susan R. Atlas, Richard C. Harvey, Stephen P. Hunger, Meenakshi Devidas, Michael J. Borowitz, Paul Bowman, William L. Carroll, Bruce Camitta, Gregory H. Reaman, and Cheryl L. Willman Blood Volume 110(11): November 16, 2007 ©2007 by American Society of Hematology

2 Figure. Figure Huining Kang et al. Blood 2007;110:1422
©2007 by American Society of Hematology

Download ppt "Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric."

Similar presentations

Www.target.cancer.gov COG Stephen Hunger, MD William Carroll, MD Gregory Reaman, MD Paul Bowman, MD Mini Devidas, PhD University of New Mexico Cheryl Willman,

COG Stephen Hunger, MD William Carroll, MD Gregory Reaman, MD Paul Bowman, MD Mini Devidas, PhD University of New Mexico Cheryl Willman,
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
by Nadine Martel, James Lee, and Philip S. Wells

by Nadine Martel, James Lee, and Philip S. Wells
Building better therapy for children with acute lymphoblastic leukemia

Building better therapy for children with acute lymphoblastic leukemia
Lucky Jain, MD, MBA  Clinics in Perinatology 

Lucky Jain, MD, MBA  Clinics in Perinatology 
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
The Role of MRD in Hematologic Malignancies

The Role of MRD in Hematologic Malignancies
The Role of MRD in Hematologic Malignancies

The Role of MRD in Hematologic Malignancies
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Similar presentations

Ads by Google